Atovaquone
Overview
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Canrenoate (K)'s dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 750 mg | 750 (750) | 12 hourly | PO | This dose is for treatment of mild-moderate PCP(pneumocystis carini pneumonia): 750mg or 5ml two times daily taken with meal. |
| 1500 mg | 1500 (1500) | 24 hourly | PO | This dose is for prevention of PCP(pneumocystis carini pneumonia): 1500mg or 10ml one daily taken with meal. |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Canrenoate (K) is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Canrenoate (K) is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Canrenoate (K)
Back to top
Previous Drug Generic - Next Drug Generic